Learn More
BACKGROUND The development and evaluation of rapid and accurate new diagnostic tools is essential to improve tuberculosis (TB) control in developing countries. In a previous study, the first release of a urine LAM-ELISA by Chemogen (Portland, USA) has been evaluated with a promising sensitivity and specificity for the diagnosis of pulmonary TB. In the(More)
First released onto the market in 2008 [1], the HIV-1 integrase inhibitor raltegravir is recommended for the treatment of HIV-1 infection in treatment-naive or experienced patients when combined with other antiretroviral agents. Raltegravir is generally well tolerated, with adverse reactions comparable to placebo [2,3]. Gastrointestinal upset, headaches,(More)
We investigated the potential of two different electronic noses (EN; code named "Rob" and "Walter") to differentiate between sputum headspace samples from tuberculosis (TB) patients and non-TB patients. Only samples from Ziehl-Neelsen stain (ZN)- and Mycobacterium tuberculosis culture-positive (TBPOS) sputum samples and ZN- and culture-negative (TBNEG)(More)
Lipoarabinomannan (LAM), a cell wall component of mycobacteria, can be detected in the urine of tuberculosis (TB) patients. Advantages of this diagnostic include the ease of sample collection and test methods. However, as with most new TB diagnostics, LAM tests have been evaluated in well-controlled laboratory settings and subsequently need assessment under(More)
  • 1